Chiron Corporation - UK Company Profile

10:52 EDT 23rd September 2017 | BioPortfolio

Chiron's diversified business model provides multiple revenue streams to balance risk, fund innovation and promote growth. Our strategic focus on cancer and infectious disease supports three product platforms - vaccines, small molecules and therapeutic proteins - and generates product candidates for our three related and complementary businesses - BioPharmaceuticals, Vaccines, and Blood Testing. Building on the proven ability of our business model to deliver solid profits, we have targeted a long-term goal of achieving a 25% EPS compound average growth rate, with a targeted through-put rate by 2006 of one new product launch every 18 months.


Centaur House, Park Lane, Cranford
Greater London
United Kingdom


Phone: +44 (0) 208 580 4000
Fax: +44 (0) 208 580 4001

News Articles [73 Associated News Articles listed on BioPortfolio]

Intrinsic4D Inc. Announces Public Sale of Substantially all of the Assets of its Operating Subsidiary and Transfer to NEX

TORONTO, ONTARIO -- (Marketwired) -- 05/11/17 -- Intrinsic4D Inc. (the "Corporation") (TSX VENTURE: IFD) provides stakeholders with an update in relation to its financial status and solvency. Publi...

Savaria Announces Resignation of Director and Appointment of New Director

LAVAL, QUEBEC -- (Marketwired) -- 07/07/17 -- Savaria Corporation (TSX: SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, is pleased to announce th...

Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Options and DSUs

TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) announces that at its Annual General Meeting on August 14, 2017 ...

Geron Corporation Reports First Quarter 2017 Financial Results and Recent Events

MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2017 and recent events. First Quarter...

NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation

REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) diso...

ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation

RAMSEY, N.J., May 30, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) announced today that its stockholders voted to approve ADMA’s previously announced acquisition of certain asset...

Global DPT vaccine Market 2017 Growth, Opportunity, Analysis, Demand, Consumption to 2027

Major Key Players are Merck & Co., Inc , Sanofi , GSK , Lanzhou Institute of Biological Products , wyeth , Chiron Pharmaceutical Pvt Ltd " Globally the market for DPT vaccine is increasing rapidly...

International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease

CARLSBAD, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies...

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

THE UNCONSCIOUS ROOTS OF CREATIVITY : By Kathryn Madden (Ed.). 332 pp. Asheville: Chiron Publications, $32.00, ISBN 9781630513856.

Total syntheses of Prelactone V and Prelactone B.

The total syntheses of natural products Prelactone-V and Prelactone-B have been accomplished by a novel Chiron approach starting from d-glucose. The synthesis involves isopropylidene acetal formation ...

Trachycladines and Analogues: Synthesis and Anti-cancer Activity Evaluation.

The synthesis of four new analogues of marine nucleoside trachycladine A was accomplished via direct regio- and stereoselective Vorbrüggen glycosylations of 2,6-dichloropurine and 2-chloropurine with...

Clinical Trials [13 Associated Clinical Trials listed on BioPortfolio]

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

To evaluate the safety and tolerability of the Chiron vaccine human immunodeficiency virus (HIV) p24(25 or 50 micrograms)/MF59 in healthy HIV-1 seronegative adults. To evaluate the immunog...

Meningococcal B Vaccination in University Students

This study is the third in a series using the MenB vaccine from the National Institute of Public Health in Norway (NIPH). The vaccine was first made in response to a high incidence of dise...

H5 Adult - Chiron Study of Bird Flu Vaccine

This study is will gather critical information on the safety, tolerability, and the immunogenicity (capability of causing an immune response) of A/H5N1 (Bird flu) virus vaccine in healthy ...

Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults

This study was designed to investigate the safety and immunogenicity of Chiron's investigational H. pylori (HP3) vaccine

Safety and Immunogenicity of Chiron Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

To compare the functional immune response 28 days after administration of one dose of Men ACWY Ad- with that of a Men ACWY PS vaccine

Companies [186 Associated Companies listed on BioPortfolio]

Chiron Corporation

Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a dif...


Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a dif...

Chiron Vision

Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a dif...

Chiron Scientific, Inc

Chiron Scientific, Inc. is a full line distributor of laboratory equipment and supplies. In addition to normal laboratory supplies, we pride ourselves in locating those hard to find and niche products...

Chiron Vaccines


More Information about "Chiron Corporation - UK" on BioPortfolio

We have published hundreds of Chiron Corporation - UK news stories on BioPortfolio along with dozens of Chiron Corporation - UK Clinical Trials and PubMed Articles about Chiron Corporation - UK for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiron Corporation - UK Companies in our database. You can also find out about relevant Chiron Corporation - UK Drugs and Medications on this site too.

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Corporate Database Quicklinks

Searches Linking to this Company Record